Aerovate Therapeutics, Inc.
Aerovate Therapeutics, Inc. (AVTE) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
avte · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Aerovate Therapeutics, Inc. (AVTE) measures how much investors pay for each dollar of the company's trailing earnings. AVTE's current PE ratio of N/A is calculated by dividing its stock price of $2.68 by its TTM earnings per share of -$2.24.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2019 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Aerovate Therapeutics, Inc.You AVTE | $78M | N/A | — | -$2.24 |
 Achilles Therapeutics plc ACHL | $61M | N/A | — | -$1.74 |
 Berkeley Lights, Inc. BLI | $87M | N/A | — | -$1.42 |
 IGM Biosciences, Inc. IGMS | $77M | N/A | — | -$3.24 |
 Insight Molecular Diagnostics Inc. IMDX | $161M | N/A | — | -$1.65 |
 Landos Biopharma, Inc. LABP | $72M | N/A | — | -$3.50 |
 Miromatrix Medical Inc. MIRO | $93M | N/A | — | -$1.45 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-4.06 | — | |
2024-12-31 FY2024 | — | $-2.44 | — | |
2023-12-31 FY2023 | — | $-2.87 | — | |
2022-12-31 FY2022 | — | $-2.10 | — | |
2021-12-31 FY2021 | — | $-0.94 | — | |
2020-12-31 FY2020 | — | $-0.39 | — | |
2019-12-31 FY2019 | — | $-0.14 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Aerovate Therapeutics, Inc. (AVTE) measures how much investors pay for each dollar of the company's trailing earnings. AVTE's current PE ratio of N/A is calculated by dividing its stock price of $2.68 by its TTM earnings per share of -$2.24.
Frequently asked questions
AVTE pe ratio · 6 questionsAVTE's current PE ratio is N/A as of 2026-06-09, based on a stock price of $2.68 and TTM EPS of -$2.24. Data sourced from Financial Modeling Prep via AVTE's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Aerovate Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09